301060.SZ
兰卫医学
SZSE · Healthcare · F 批发零售 · CN
CNY 11.43
−0.61%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | 1.4B | 1.7B | 1.7B | 4.2B |
| Cost of Revenue | 1.0B | 1.1B | 1.4B | 1.3B | 2.4B |
| Gross Profit | 355.5M | 347.0M | 384.7M | 348.3M | 1.8B |
| Operating Expenses | |||||
| R&D Expense | 38.0M | 41.1M | 60.0M | 48.9M | 109.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 193.2M | 193.7M | 215.3M | 203.4M | 355.5M |
| Selling & Marketing Expense | 81.7M | 84.7M | 88.9M | 98.7M | 184.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 319.3M | 325.9M | 376.6M | 359.1M | 662.2M |
| Cost and Expenses | 1.3B | 1.4B | 1.7B | 1.7B | 3.1B |
| Operating Income (EBIT) | 67.8M | 14.9M | (69.3M) | (135.8M) | 949.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 63.6M | 10.5M | (102.8M) | (153.2M) | 904.4M |
| Income Tax Expense | 32.1M | 26.0M | (4.2M) | 8.5M | 165.4M |
| Bottom Line | |||||
| Net Income | 14.2M | (30.7M) | (109.4M) | (141.6M) | 617.3M |
| Earnings from Cont. Ops | 31.5M | (15.4M) | (98.6M) | (161.7M) | 739.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 14.2M | (30.7M) | (109.4M) | (141.6M) | 617.3M |
| Per Share | |||||
| Basic EPS | CN¥0.03 | (CN¥0.08) | (CN¥0.27) | (CN¥0.35) | CN¥1.54 |
| Diluted EPS | CN¥0.03 | (CN¥0.08) | (CN¥0.27) | (CN¥0.35) | CN¥1.54 |
| Revenue Per Share | CN¥3.38 | CN¥3.77 | CN¥4.30 | CN¥4.14 | CN¥10.48 |
| Shares | |||||
| Basic Shares Outstanding | 410.1M | 384.3M | 405.3M | 404.5M | 400.5M |
| Diluted Shares Outstanding | 410.1M | 384.3M | 405.3M | 404.5M | 400.5M |
| Profitability Metrics | |||||
| EBITDA | — | 105.5M | 20.7M | (68.5M) | 1.0B |
| D&A | — | 90.6M | 90.0M | 67.3M | 82.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026